SCHEMBL2214161

SCHEMBL2214161

CCCCc1c2c(=O)n(Cc3ccccc3)[nH]c2cc(=O)n1Cc1cc(OC)cc(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 8/20 0.46
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
ADORA3 P0DMS8 4/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C8 P10632 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPK8 P45983 1/20 0.36
CYBB P04839 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2216760 0.85 NOX4 (0.47) NOX4CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL2219166 0.84 NOX4 (0.46) NOX4NPSR1CYBB
SCHEMBL2210971 0.81 NOX4 (0.72) NOX4PDE4APDE4BPDE4CPDE4D
SCHEMBL2217748 0.78 NOX4 (0.53) NOX4CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL2216533 0.76 KMT2A (0.43) NOX4CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL2217970 0.75 NOX4 (0.42) NOX4CYP2C9CYP2C19CYBBMEN1
SCHEMBL2220132 0.74 NOX4 (0.46) NOX4ADORA3CYP2C9CYP2C19CYBB
SCHEMBL2219028 0.73 NOX4 (0.66) NOX4CYP3A4MAPTCYBB
SCHEMBL2211290 0.73 NOX4 (0.43) NOX4PDE4APDE4BPDE4CPDE4D
SCHEMBL2216504 0.72 NOX4 (0.57) NOX4PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP claimed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US claimed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US claimed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 US claimed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US claimed
EP-2166009-A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors GENKYO TEX SA (CH) 2010-03-24 EP claimed
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP disclosed
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US disclosed
EP-2342203-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex SA (CH) 2011-07-13 EP disclosed
WO-2010035220-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO disclosed
WO-2010035220-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO disclosed
EP-2166009-A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors GENKYO TEX SA (CH) 2010-03-24 EP disclosed
EP-2166009-A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors GENKYO TEX SA (CH) 2010-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB NOX4 2/4885PDE4A 288/4885PDE4B 370/4885
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB NOX4 2/4885PDE4A 288/4885PDE4B 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.